Asia Pacific Alzheimer's Diagnosis and Treatment Segmentation
Diagnosis Method (CT Scan, Magnetic Resonance (MRI), PET Scan, Electroencephalography (EEG), Cerebrospinal Fluid (CSF) Test)
The Asia Pacific Alzheimer’s diagnosis and treatment market is segmented and analyzed for demand and supply by diagnosis method (CT scan, magnetic resonance (MRI), PET scans, electroencephalography (EEG), cerebrospinal fluid (CSF) test, and others. Out of the six types of diagnosis methods, the PET scans segment is estimated to gain the largest market size of USD 898.8 million by the end of 2033 by growing at a CAGR of 9.5% over the projected time frame. Moreover, the segment is to garner a revenue of USD 333.8 million in 2022. Alzheimer's disease's neuropathological signature is brain amyloid (AD). By radiolabeled tracers, it can be detected using in vivo positron emission tomography (PET) imaging. Moreover, PET scanners help in early detection of dementia. Moreover, it aids the better scanning of the brain and improves cognitive neurosciences. The growth of the segment is attributed to the benefits of the PET scans in the detection of dementia. In 15/44 clinical subjects (34%), amyloid PET imaging changed the diagnosis. From around 73% pre-scan to nearly 93% post-scan, the average level of diagnostic confidence increased by around 20%. Furthermore, the growth of the segment can also be credited to the higher number of PRT scanners present in the region. In 2020 there were nearly 550 PET scanners in Japan.
Treatment Provider (Hospitals, Specialty Clinics, Home Care)
The Asia Pacific Alzheimer’s diagnosis and treatment market is also segmented and analyzed for demand and supply by treatment provider hospitals, specialty clinics, and home care. Amongst these three segments, the hospitals segment is expected to garner a market revenue of USD 2761.4 million by the end of 2033 by growing at a CAGR of 14.1% over the forecast period. Additionally, the segment generated a revenue of USD 693.2 million in 2022. Hospitals can provide a better care to the patient suffering from Alzheimer and dementia. In hospital, their condition can be monitored all the time. The segment growth is attributed to the higher admission of dementia affected people in the hospitals. People with dementia currently occupy 1 in every 4 hospital beds. People with dementia frequently have lengthier hospital stays, delayed discharges, and less independence.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment |
|
|
By Diagnosis Method |
|
|
By Treatment Provider |
|
|
By Distribution Channel |
|
